Based on these findings, a phase I study (NCT01623349) was conducted in 26 BC patients, including 14 TNBC, to evaluate the combination of the PI3K inhibitor buparlisib and the PARP inhibitor olaparib. This evidence concerns the gene PIK3CG and breast cancer.